<div id="readability-page-1"><p><span>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)</span> had its price objective dropped by research analysts at Leerink Partners  from $80.00 to $70.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Leerink Partners' target price would suggest a potential upside of 211.18% from the stock's current price.</p><ul><li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li></ul><p>RARE has been the topic of several other research reports. Wells Fargo &amp; Company decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday. Truist Financial dropped their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, November 5th. Barclays lowered their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an &#34;overweight&#34; rating for the company in a report on Monday, November 24th. TD Cowen reduced their price objective on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, November 5th. Finally, Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $75.19.</p><p><b>View Our Latest Report on Ultragenyx Pharmaceutical</b></p><h2>Ultragenyx Pharmaceutical Stock Up 14.1%</h2><p>NASDAQ:RARE traded up $2.78 during trading hours on Tuesday, reaching $22.50. The company had a trading volume of 5,898,943 shares, compared to its average volume of 1,462,417. The firm has a market capitalization of $2.17 billion, a PE ratio of -3.76 and a beta of 0.16. The stock has a 50-day moving average of $33.66 and a two-hundred day moving average of $32.11. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $46.50. </p><p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The business had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm's revenue was up 14.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.40) earnings per share.  As a group, sell-side analysts expect that  Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year. </p><h2>Insider Transactions at Ultragenyx Pharmaceutical</h2><p>In other news, CFO Howard Horn sold 7,942 shares of the business's stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer owned 98,227 shares of the company's stock, valued at $3,095,132.77. The trade was a 7.48% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Corporate insiders own  5.50% of the company's stock. </p><h2>Institutional Trading of Ultragenyx Pharmaceutical</h2><p>Several hedge funds have recently bought and sold shares of RARE. Jacobs Levy Equity Management Inc. increased its position in shares of  Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock worth $65,205,000 after purchasing an additional 1,864,164 shares during the last quarter.  Norges Bank acquired a new position in  Ultragenyx Pharmaceutical during the second quarter worth $35,765,000.  Adage Capital Partners GP L.L.C. raised its position in  Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after acquiring an additional 965,919 shares in the last quarter.  Assenagon Asset Management S.A. lifted its stake in  Ultragenyx Pharmaceutical by 439.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock valued at $42,314,000 after acquiring an additional 947,865 shares during the last quarter.  Finally, Vestal Point Capital LP bought a new stake in shares of  Ultragenyx Pharmaceutical in the 3rd quarter valued at about $22,560,000. 97.67% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Ultragenyx Pharmaceutical News Summary</h2><p>Here are the key news stories impacting Ultragenyx Pharmaceutical this week:</p><ul>   <li><span>Positive Sentiment: </span>Analysts remain constructive despite cuts — Jefferies cut its target from $114 to $63 but kept a &#34;Buy&#34; rating; Wells Fargo cut its target from $65 to $45 but kept an &#34;Overweight&#34; rating. These retained positive ratings suggest some firms still see long‑term value or upside after the selloff. <i></i><span>Benzinga</span></li>    <li><span>Neutral Sentiment: </span>Unusual options activity — investors bought 3,801 call contracts (≈+154% vs. average), which could reflect speculative bets on a rebound, hedging, or directional trading amid large share volatility. (No article link)</li>    <li><span>Negative Sentiment: </span>Phase 3 failure — Ultragenyx said neither Orbit nor Cosmic met the primary endpoint of reducing annualized clinical fracture rate vs. placebo or bisphosphonates, respectively; this is the direct clinical reason for the stock drop. <i></i><span>Company Release</span></li>    <li><span>Negative Sentiment: </span>Immediate market impact — media reports and market wires show a sharp share plunge, a trading halt, and heavy volume as investors priced in the failed trials; the company lost a large portion of market value in short order. <i></i><span>Reuters</span></li>    <li><span>Negative Sentiment: </span>Operational consequences — Ultragenyx signaled &#34;significant&#34; cutbacks following the failed study, which could reduce near‑term expenses but also reflects a re‑prioritization and potential delays to other programs. <i></i><span>BizJournals</span></li> </ul><h2>Ultragenyx Pharmaceutical Company Profile</h2> (Get Free Report)<p>Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.  </p><p>The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Ultragenyx Pharmaceutical</li><li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>Trump’s new AI budget just passed — one stock could soar</li><li>Terrifying reason Trump killed the U.S. penny?</li><li>The IRS Strategy Trump Quietly Backed for Retirement Wealth</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?</h2><p>Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.</p><p>While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RARE

<p>Leerink Partners has lowered its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $80.00 to $70.00 while maintaining an "outperform" rating. This suggests a potential upside of 211.18% from the current stock price. Other analysts have also adjusted their targets, with Wells Fargo reducing it to $45.00 and Truist to $90.00. The stock recently traded at $22.50, up 14.1%, with a market cap of $2.17 billion. The company reported a quarterly EPS of ($1.81), missing estimates, and revenue of $159.93 million, below expectations.</p>

Leerink Partners Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $70.00